Investor Latest press releases 18 NOVEMBER 2021 13:46 EST Cellectis and Cytovia Extend Partnership in China to Develop iPSC-Derived NK Cells Genetically Modified by TALEN® READ THE PRESS RELEASE 11 NOVEMBER 2021 5:47 PM EST Society for Immunotherapy of Cancer (SITC): Cellectis presents the first preclinical data of UCARTMESO, its product candidate of allogeneic CAR-T cells targeting mesothelin for the treatment of solid tumors READ THE PRESS RELEASE 04 NOVEMBER 2021 2:57 PM EST Cellectis publishes its financial results for the third quarter and for the first nine months of 2021 READ THE PRESS RELEASE Events to come 06 DÉCEMBRE 2021 ‐ 07 DÉCEMBRE 2021 JMP Securities Hematology and Oncology Summit EN SAVOIR PLUS 14 DÉCEMBRE 2021 ‐ 16 DÉCEMBRE 2021 Cell Therapy Analytical Development Summit EN SAVOIR PLUS Présentation corporate Cellectis est coté sur deux marchés: le marché Euronext Growth à Paris (ticker: ALCLS) et le Nasdaq Global Market à New-York (ticker: CLLS). Cellectis ADS (Nasdaq) TICKER: CLLS $8.6900 -0.0300 (-0.3440%) PREV. CLOSE 8.7200 VOLUME 81,714 HIGH 8.7850 CAPITALIZATION 395.180M Last Update: about 2 days ago Cellectis (Euronext Growth Paris) TICKER: ALCLS €7.6900 -0.1500 (-1.9133%) PREV. CLOSE 7.8400 VOLUME 96,798 HIGH 7.7900 CAPITALIZATION 349.705M Last Update: 2 days ago VOIR INFORMATIONS BOURSIÈRES ANALYSTES FINANCIERS Barclays - Gena Wang Citi - Yigal Nochomovitz Goldman Sachs - Salveen Richter Guggenheim - Michael Schmidt Jefferies – Kelly Shi Jones Trading - Soumit Roy Kempen - Ingrid Gafanhão Ladenburg – Wangzhi Li Oddo BHF - Martial Descoutures Oppenheimer – Hartaj Singh Portzamparc – Christophe Dombu RW Baird - Jack Allen Wells Fargo – Nick Abbott William Blair – Raju Prasad CONTACTS CELLECTIS Eric Dutang +1 (646) 630 1748 investors@cellectis.com CONTACTS CITIBANK ADR Intermédiaires & Investisseur US: +1 212 723 5435 UK: +44 207 500 2030 citiadr@citi.com SOCIÉTÉ GÉNÉRALE SECURITIES SERVICES - ACTIONS ORDINAIRES Centre d'appels disponible du lundi au vendredi de 8h30 à 18h00 02 51 85 67 89 Restez informés Subscribe to our email alert service REGISTER NOW LEGAL NOTICECONTACTCOMMUNITY RULES Subsidiary: Calyxt Inc.